Looks like you’re on the UK site. Choose another location to see content specific to your location
Novo Nordisk reports sales growth during 2016
Novo Nordisk has announced its financial results for 2016, during which it recorded an annual sales total of 111.8 billion Danish kroner (12.93 billion pounds).
This represented a six percent year-over-year increase in local currencies and a four percent rise in terms of Danish kroner, while adjusted operating profit growth of six percent in local currencies was achieved.
The company was able to meet its financial guidance for the year, despite strong market headwinds in the US that necessitated a revision of its long-term financial targets.
Key highlights of the last year include the publication of positive cardiovascular safety data for Tresiba, key regulatory approvals for Xultophy and Fiasp, and the appointment of Lars Fruergaard Jorgensen as its new president and chief executive officer.
The business leader said: "2016 was a challenging year … However, 2016 was also a year in which we announced very encouraging clinical data for our key products, providing a solid foundation for future growth."
In 2017, Novo Nordisk anticipates reported sales growth of between one and six percent, as measured in Danish kroner.
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips
and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard